Background: Smoking among patients with cancer is associated with poor outcomes, however, smoking cessation interventions have had limited success.
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| I NT ROD UCTI ON
Tobacco smoking is the greatest risk factor for upper aerodigestive malignancies. [1] [2] [3] [4] Continued tobacco smoking during and after cancer treatment is associated with poor outcomes, including higher risk of recurrence, second primary tumors, death, [5] [6] [7] treatment-related morbidities, 7, 8 and lower quality of life. 9 Many patients with head and neck or thoracic cancers, however, continue to smoke after diagnosis. [10] [11] [12] [13] [14] Advocating and supporting smoking cessation among these patients is increasingly recognized as an essential component of multidisciplinary cancer care, [15] [16] [17] [18] and successful tobacco smoking cessation, even after diagnosis, is associated with improved outcomes. 5, 11, 16 Among patients receiving radiotherapy, smoking abstinence during treatment may increase tumor radiosensitivity and, therefore, enhance response to treatment. 7, [19] [20] [21] [22] [23] Smoking cessation interventions to date among patients with cancer, however, have had only limited success, 24 despite evidence that the time around cancer diagnosis is a "teachable moment" during which patients are more likely to quit than at other times in their lives. 25 Interventions that
show promise in initial research use combination therapies (eg, both counseling and pharmacotherapy). 24, [26] [27] [28] [29] [30] [31] [32] Several smoking cessation strategies have shown efficacy in noncancer populations by utilizing mobile technology, 33 contingency management, 34, 35 or combination nicotine replacement therapy 36 but have not yet been evaluated among patients with head and neck or thoracic cancer. We designed a pilot study to determine whether a novel combination smoking cessation intervention tailored to patients with cancer would be both feasible and effective in increasing smoking abstinence for patients with head and neck or thoracic cancer during radiotherapy. Long-term smoking cessation was also assessed.
| M ATE RI ALS AN D ME THO DS

| Participants and design
This pilot study was a randomized, controlled, 2-arm trial of a comprehensive smoking cessation intervention compared with enhanced usual care (ClinicalTrials.gov number NCT02188563). This study was approved by the Johns Hopkins Hospital Institutional Review Board.
Participants were enrolled from May 2014 through March 2015. Eligible patients were 18 years or older, English speaking, able to provide informed consent, had an incident head and neck or thoracic malignancy, and planned radiotherapy for 5 or more weeks at Johns Hopkins Cancer Treatment Centers, and reported smoking cigarettes within the previous 14 days.
| Study procedures
Participants were randomized to enhanced usual care ("control") or intervention groups using 1:1 block randomization with stratification by cancer site (head and neck versus thoracic) and sex. Randomization was generated using SAS software (Cary, NC) and concealed in sequentially numbered opaque envelopes until study group assignment.
Both groups were followed closely for the first 8 weeks of the study, with study visits at baseline and weekly for 8 weeks, and then had long-term follow-up visits at 3, 6, and 12 months (see Figure 1) . The control group received a single counseling session at the baseline visit, whereas the intervention group received intensive counseling, pharmacotherapy support, and other interventions at baseline and throughout weeks 1 to 8 (see Figure 1) .
The baseline visit for the control group comprised 4 intervention components to constitute enhanced usual care: (1) brief counseling by a trained tobacco treatment specialist consistent with the "5 As" recommended by the United States Department of Health and Human Services 37 ; (2) a smoking cessation workbook tailored to patients with cancer patients; (3) contact information for local and national smoking cessation resources, including some offering free nicotine replacement therapy; and (4) mental health screening to evaluate depressive symptoms, whereby individuals scoring 8 on the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) 38, 39 were offered referral to psychiatric services. At every visit, surveys were administered to ascertain smoking behavior and use of smoking cessation resources, and exhaled carbon monoxide testing was administered for biochemical confirmation of smoking status (Micro1 Smokerlyzer; Bedfont Scientific, Kent, England; cost for device $1398.15). All participants were offered small gift cards for each completed study visit ($10 at baseline and $5 at follow-up). Tobacco treatment specialists are professionals who are specially trained to provide treatment for individuals seeking to stop using tobacco (more information at ctttp.org).
The intervention group had the same study visit schedule, surveys, exhaled carbon monoxide administration, and mental health screening as the control group. However, the components of each study visit were different, and there were up to 4 additional daily visits during the first week. At baseline, the intervention group received the smoking cessation workbook and underwent intensive tobacco treatment specialist motivational interviewing, with brief follow-up motivational interviewing sessions at subsequent study visits, daily for the first week, then weekly for 8 weeks. Other additional interventions received included: enrollment in the National Cancer Institute's free smokefreetxt text-messaging program (smokefree.gov); contingency management at each visit, by which participants received $5 gift cards for biochemically confirmed smoking abstinence; and guided pharmacotherapy. Pharmacotherapeutic options offered were combination nicotine replacement therapy (patch/gum, patch/lozenge, or patch/nasal spray), bupropion, and varenicline. Participants receiving combination nicotine replacement therapy were instructed to use the patch daily, and to also use the nicotine gum, lozenges, or nasal spray as needed. Medication recommendations were based on mental health screening, comorbidities, and allergies, with oversight by a physician with expertise in tobacco cessation (F.K.; Supporting Information Figure S1 ). Over-the-counter nicotine replacement therapy was provided for free (estimated cost per participant $240), and prescriptions provided for other medications. Participants were permitted to opt-out of intervention components.
Medical record abstraction was performed to evaluate clinical characteristics of interest. Participants with either former or current illicit injection drug use were considered to have "history of injection drug use." "Mucositis" was considered Common Terminology Criteria for Adverse Events version 3.0 (CTCAE) 40 grade 2 or higher mucositis/stomatitis (including esophagitis) at any time during weeks 1 to 8. This pilot study originally had a target sample size of 60. Enrollment was slower than expected, however, and at the interim analysis (once 30 people were enrolled), the decision was made to stop the study.
| Outcome measures
The primary outcome for this study was 7-day smoking abstinence at 8 weeks from the baseline study visit. Participants were considered abstinent if they both reported not smoking in the previous 7 days and had exhaled carbon monoxide 8 parts per million (ppm). 41 Secondary outcomes included smoking abstinence at other time points, smoking intensity (total cigarettes per previous 7 days), the reduction from baseline thereof, and total cigarettes smoked.
| Statistical analysis
Descriptive variables were reported as number and percent, or median and interquartile range (IQR). Characteristics of the intervention and control groups were compared using 2-sided Fisher's Exact Tests for categorical variables. Differences in medians were compared using Wilcoxon RankSum Tests. Prevalence of smoking abstinence was compared using Fisher's Exact Test. Change from baseline in smoking intensity was compared using repeated-measures analysis of variance. Characteristics associated with smoking abstinence were analyzed for short-term (weeks 1-8 combined) and long-term (3 months, 6 months, and 12 months combined) study visits separately, using time-series panel data logistic regression models 42 to account for the repeated visits. Unadjusted and adjusted odds ratios (ORs) were reported with 95% confidence intervals (CI). Characteristics associated with smoking intensity were similarly evaluated with time-series panel data negative binomial regression models, and incidence rate ratios (IRRs) reported. A Kappa statistics was calculated to compare 
| R ES ULT S
| Study population
There were 30 participants in this study, 19 randomized to the intervention group and 11 to the control group (see Figure 1) . One participant in the control group was lost to follow-up after the baseline visit; therefore, the analytic cohort comprised 29 participants (19 intervention and 10 control; Supporting Information Figure S2 ). Baseline demographic and disease-related characteristics of the 2 study groups are shown in Table 1 . Median age was 55 years (IQR 52-62 years). The majority of participants were men (N 5 18; 62%) and white (N 5 18; 62%). Median pack-years of smoking was 48 (IQR 28-64). Nearly all (N 5 27; 93%) participants reported cutting back on smoking when diagnosed with cancer. Although most participants (N 5 22; 76%) had been advised by a healthcare worker to quit smoking in the past year, only 1 participant reported that a healthcare worker followed up on that recommendation. Most (N 5 19; 66%) participants had tried electronic cigarettes (e-cigarettes, also called vaping) before study enrollment, and the majority of these individuals (N 5 16; 84%) reported using e-cigarettes to "cut down on smoking." The HADS-D screen was positive for 9 patients, of whom 3 accepted psychiatry referral. Baseline characteristics were statistically similar by study group, with the exception that more intervention participants reported post-high school education (53% vs 10%; P 5 .04).
| Interventions received and resources used
Overall, 95.1% (292/307) of planned study visits were completed, excluding the 12 study visits among 7 participants not completed due to the participants' death before the study completion.
As expected, participants in the intervention group received significantly more cessation support during weeks 1 to 8 than those in the control group (see Figure 2) . During this time, the intervention group received more motivational interviewing than the control group (median 87 vs 15 minutes; P < .001). A higher proportion of patients in the intervention versus the control group used combination nicotine replacement therapy (47% vs 10%; P 5 .10) and textmessaging cessation support (79% vs 0%; P < .001). Although consistent medication use was low in both groups, participants in the intervention group used smoking cessation medications on more days than the control group (median 33% vs 11% of days; P 5 .06). By week 8, only 2 participants used medications; these were both in the intervention group, and both used a combination of the nicotine patch and nicotine gum. 
| Smoking abstinence
Participants in the intervention group were significantly more likely to abstain from cigarette smoking than those in the control group at week 8, the primary study end point (74% vs 30%; P 5 .046; Figure 3 ). In fact, the intervention participants were more likely to abstain from smoking at every follow-up study visit during weeks 1 to 8. Additionally, the proportion of intervention group participants who abstained from smoking increased or was stable each subsequent week of follow-up during weeks 1 to 8, which was not true of the control group (see Figure 3 ). Considering long-term outcomes (3, 6 , and 12 months), the proportion of participants who abstained from smoking remained higher in the intervention group compared with the control group but was not significantly different at any time point (see Figure 2) . In both groups, the proportion of participants who abstained from smoking after the intervention ended decreased over time in long-term follow-up (see Figure 3) . Although smoking abstinence was not maintained by most participants, some in the intervention group did achieve long-term cessation. At 12 months, 31% (4/13) of the intervention group participants still in follow-up were abstinent compared to none of the control group participants (0/8).
| Smoking intensity
Benefits to the intervention group were similarly apparent when considering the intensity of cigarette smoking during weeks 1 to 8 (see Figure 4) . Compared with the control group, participants in the intervention group smoked significantly fewer cigarettes per week at week 8 (median 0 vs 10; P 5 .04), smoked fewer total cigarettes during weeks 1 to 8 (median 49 vs 156; P 5 .09), and had a greater reduction in number of cigarettes smoked per week at week 8 compared with baseline (median 228 vs 214; P 5 .28).
| Characteristics associated with smoking abstinence and intensity, short term
Participant characteristics associated with smoking abstinence during weeks 1 to 8 after the baseline study visit were evaluated (Table 2 ). Assignment to the intervention group was associated with nearly 5-fold higher odds of smoking abstinence (unadjusted OR 4.83; 95% CI 1.31-17.76). The only other factor associated with improved smoking F IGUR E 2 Comparison of the proportion of control and intervention participants who used smoking cessation medications and resources during weeks 1 to 8 of the study period. Text messaging and smoking cessation medications were provided to intervention group participants and recommended but not provided to the control group participants. *P < .05 for difference in proportion of control versus intervention participants who used the resources. Combination nicotine replacement therapy (NRT) included gum/patch (7 participants), lozenge/patch (2 participants), or nasal spray/patch (1 participant). Single nicotine replacement therapy included patch (5 participants), lozenge (3 participants), or gum (1 participant) alone F IGUR E 3 Comparison of the proportion of control and intervention participants who abstained from smoking during the previous week (as confirmed by exhaled carbon monoxide monitoring) at each study visit. *Primary study endpoint of 8 weeks. P 5 .046 for difference in proportion of abstinent control versus intervention participants (30% vs 74%) cessation was being married (OR 4.78; 95% CI 1.46-15.63), whereas a history of depression (OR 0.16; 95% CI 0.03-0.95) or injection drug use (OR 0.04; 95% CI 0.005-0.28) were both associated with lower likelihood of smoking abstinence. Current depressive symptoms, as measured by HADS-D 8, was not associated with smoking cessation (OR 1.03; 95% CI 0.85-1.25). In the adjusted model, participants in the intervention group remained substantially more likely to be abstinent (adjusted OR 14.70; 95% CI 3.56-60.76), whereas those with a history of depression (adjusted OR for abstinence 0.16; 95% CI 0.03-0.97) or injection drug use (adjusted OR 0.04; 95% CI 0.004-0.29) were less likely to abstain from smoking. As expected, the odds of abstinence increased each successive week that the participants progressed through the study protocol and radiotherapy (adjusted OR per each subsequent study visit 1.52; 95% CI 1.29-1.80). The effect of study group on abstinence was similar across study visits (eg, there was no interaction between study group and study visit, p interaction 5 0.60).
Characteristics associated with smoking intensity were also examined. During weeks 1 to 8, the rate of smoking was 59% lower among participants in the intervention group compared to the control group (unadjusted IRR for the number of cigarettes smoked per week 0.41; 95% CI 0.17-0.98; Table  3 ). Other factors associated with smoking fewer cigarettes included older age (IRR 0.32; 95% CI 0.16-0.65 for 55 vs <55 years), being married (IRR 0.43; 95% CI 0.19-1.00), and e-cigarette use in the previous week (IRR 0.45; 95% CI 0.26-0.79). Participants with a history of injection drug use (IRR 3.86; 95% CI 1.79-8.30) or depression (IRR 3.61; 95% CI 1.70-7.70) smoked more cigarettes. In adjusted analysis, assignment to the intervention group continued to be associated with a strong decrease in smoking intensity. Indeed, after adjusting for other factors, the rate of cigarette use was 84% lower in intervention than control participants (adjusted IRR 0.16; 95% CI 0.06-0.40). A history of injection drug use (adjusted IRR 0.04; 95% CI 0.004-0.29) or depression (adjusted IRR 0.16; 95% CI 0.03-0.97) both remained associated with higher rates of smoking, but e-cigarette use was no longer a predictor of smoking intensity in the adjusted model (Table 3 ). Similar to smoking abstinence, smoking intensity decreased with each week the participants were in the study (adjusted IRR per week 0.76; 95% CI 0.64-0.89), without a significant interaction between study group and visit (P 5 .84).
| Characteristics associated with smoking abstinence and intensity, long term
During long-term follow-up (3, 6, and 12-month study visits), individuals in the intervention group remained more likely to be abstinent from smoking compared with those in F IGUR E 4 Box plot of the number of total cigarettes smoked in the previous week among the control group participants compared with the intervention group participants, as reported at each study visit. Solid boxes represent the interquartile range (IQR); white lines represent medians; "whiskers" represent maximum and minimum values, excluding outliers; dots represent outliers (eg, data points >1.5 times the IQR above the 75th percentile or below the 25th percentile). *Primary study endpoint of 8 weeks. P 5 .04 for difference in median cigarettes smoked in the previous week for the control group versus the intervention group participants (0 vs 10) Table S1 ). Of note, all participants with head and neck cancer experienced mucositis (15 of 15; 100%) compared with only 5 of 13 patients (38%) with thoracic cancer (P < .001), which may account for the observed site-specific differences.
| Exhaled carbon monoxide
Overall, 81% (245/301) of smoking status self-reports were accompanied by contemporaneous exhaled carbon monoxide measurements. There were just 2 instances in which a participant reported abstinence but had exhaled carbon monoxide >8 ppm (Supporting Information Table S2 ). Using exhaled carbon monoxide 8 ppm as consistent with smoking abstinence, 41 kappa was 0.69 (SE 0.06), indicating substantial agreement. Exhaled carbon monoxide 8 ppm had 71.3% (95% CI 62.7%-78.9%) sensitivity and 98.3% (95% CI 93.9%-99.8%) specificity for self-reported abstinence, and self-reported abstinence had 98.3% (95% CI 93.9%-99.8%) sensitivity and 70.9% (95% CI 62.2%-78.6%) specificity for exhaled carbon monoxide 8 ppm.
| DI S CU S S IO N
This comprehensive smoking cessation intervention significantly increased smoking abstinence and decreased smoking intensity among individuals undergoing treatment for upper aerodigestive cancers, with many participants achieving smoking cessation during radiotherapy and some maintaining long-term abstinence. This is the first study to combine counseling, pharmacotherapy, including combination nicotine replacement therapy, mobile technology, and contingency management in a smoking cessation intervention for patients with cancer, and is one of the most intensive interventions described to date for this population. The success of this intervention may inform the design of future smoking cessation programs for patients with cancer. Previous studies of smoking cessation among patients with cancer have had limited success, but do suggest that combination therapies are more successful than monotherapies for this challenging population. 24 Although it is not possible from our study to determine the relative importance of the various intervention components, the successful shortterm reductions in smoking observed may be attributable to its comprehensive nature rather than to any single element. The intensity of our intervention was likely another key factor in increasing abstinence rates, as differences in smoking abstinence and intensity between the intervention and control groups paralleled the intervention's intensity level over time. These differences were most evident during the first 8 weeks of the study, when counseling and other support were provided at least weekly for the intervention group. Subsequently, the decrease in study visit frequency and the withdrawal of intervention components after 8 weeks coincided with an observed decrease in long-term abstinence rates for both groups. It is conceivable that abstinence rates for intervention participants would have remained high had the intervention continued. More study will be needed to determine the optimal duration of smoking cessation support after cancer treatment. The impact of the stronger educational background among intervention participants is unclear, as education was not associated with smoking-related outcomes.
The efficacy of our intervention during radiotherapy is particularly noteworthy when considering the detrimental effects of cigarette smoking on tumor response to radiation and on survival outcomes after radiation. Radiation-induced cell death is dependent on oxygen present in tumor tissues. 43 Carbon monoxide from cigarette smoking leads to carboxyhemoglobin formation, reducing the oxygen-carrying capacity of hemoglobin, and resulting in tissue hypoxia that hampers the ability of radiation to kill cancer cells, which is termed "hypoxic radioresistance." [19] [20] [21] Clinical studies of patients with head and neck cancer undergoing radiation who were smokers before treatment have demonstrated an association of smoking during radiation with worse survival and locoregional control. 7, 11, 44, 45 This both supports the hypoxic radioresistance theory and highlights other ill effects of cigarette smoking on tumor biology and patients' ability to tolerate treatment. 7, 20, 46 It follows, then, that an efficacious smoking cessation intervention delivered throughout radiotherapy, such as we describe here, may have the potential to improve survival outcomes, possibly even independent of smoking relapse postradiation, and warrants further study as an additional modality of cancer treatment. We describe several psychosocial risk factors for persistent smoking, which are useful in identifying patients who may require more intensive resources to achieve abstinence during treatment. Injection drug use history emerged as a risk factor for smoking behaviors. This is not surprising, as tobacco smoking is common but quit rates are low among current and former injection drug users. 35 Unmarried participants in our study also smoked more cigarettes and were less likely to quit, consistent with previous research. 47 Patients with history of injection drug use or who are unmarried should be considered higher risk for continued smoking and may benefit from mobilization of any available social support resources. Two modifiable risk factors for smoking that were identified during the study, highlighting opportunities to intervene and optimize conditions for smoking cessation, are a history of depression and current pain. Depression is frequently comorbid with tobacco smoking 48, 49 and afflicts many patients with upper aerodigestive cancer, with around 40% of patients with head and neck and lung cancer screening positive for depressive symptoms. 50, 51 Importantly, there is some evidence that treating depression while providing smoking cessation support may increase smoking abstinence. 52 Interestingly, a previous diagnosis of depression but not HADS-D score at enrollment was associated with smoking in our study, suggesting that a preexisting mood disorder is more relevant to smoking outcomes than potentially transient depressive symptoms among patients with newly diagnosed cancer. Pain has been shown to motivate smoking behavior, 53 and patients with cancer who smoke report higher pain scores than those who do not. 47 Furthermore, those with higher pain scores smoke more, as confirmed in our study. 54 We also found that participants who experienced mucositis during treatment had poor long-term smoking outcomes, which may be related to the severe pain attributable to this common treatment-related toxicity that disproportionately affects patients with head and neck cancer. 55 Although the relationship between chronic pain and smoking is complex, 56 the impact of successful pain management on long-term abstinence among cancer survivors should be explored. E-cigarettes have recently emerged as a popular alternative to traditional cigarettes. The impact of e-cigarette use on smoking behaviors among patients with cancer specifically is not well understood but initial evidence suggests that ecigarette use neither improves abstinence rates nor decreases smoking intensity. 57, 58 Before enrollment, e-cigarette use was common among study participants and was motivated by a desire to quit or cut down on smoking. During the intervention, e-cigarette use did not increase abstinence but was associated with lower smoking intensity; however, this was not significant after adjustment for other factors, and was not sustained in long-term follow-up. Another recent study of patients with head and neck cancer describes similar findings. 58 Although intriguing, these initial results do not yet justify recommending e-cigarettes to aid smoking cessation but rather highlight the need for further investigation of how these increasingly popular devices impact smoking behaviors among patients with cancer. Despite abundant evidence that smoking is associated with worse outcomes for patients with cancer [5] [6] [7] 45 and strong recommendations that cessation support be integrated into cancer treatment, 15, 17 clinical support for smoking cessation is inconsistent. Many U.S. cancer treatment centers lack tobacco dependence treatment services and few oncologists report providing support beyond advising patients to quit. 59, 60 Indeed, only 1 participant in our study reported follow-up from a healthcare provider on a recommendation to quit smoking in the previous year. Reasons that tobacco dependence treatment is often overlooked are likely systemic, including deficits in funding, expertise, and infrastructure 60,61 but may also reflect an undercurrent of pessimism given the limited success thus far of smoking cessation interventions for patients with cancer. 24 Our study suggests that it is indeed possible to help these patients quit through intensive combination therapy, at least during treatment. The time-intensive nature of our intervention also highlights the significant resource commitment that may be required to integrate efficacious smoking cessation support into cancer treatment. Strengths of this study include the comprehensiveness and intensity of the intervention. The excellent follow-up provides a detailed picture of participant smoking behavior throughout cancer treatment. Exhaled carbon monoxide monitoring contributes an additional degree of objectivity to selfreported smoking status. The small and heterogeneous study population, however, limits broad generalizability and analysis of long-term disease-related outcomes.
| CON CLU S IO NS
This comprehensive and intensive smoking cessation intervention decreased smoking among patients with tobaccorelated upper aerodigestive cancers undergoing radiotherapy. Its success may inform the design of tobacco addiction treatment programs for patients with cancer. Further research is necessary to refine this intervention and ultimately to determine whether efficacious smoking cessation interventions during cancer treatment may prospectively improve survival.
